Nominations to the Advisory Committee on Blood Safety and Availability, 23720-23721 [E9-11675]
Download as PDF
<![CDATA[
23720
Federal Register / Vol. 74, No. 96 / Wednesday, May 20, 2009 / Notices
License Number: 017470NF.
Name: CTX Expres, Inc.
Address: 2450 W. Main St., #202,
Alhambra, CA 91801.
Date Revoked: April 30, 2009.
Reason: Surrendered license
voluntarily.
License Number: 020068NF.
Name: Ice Express LLC. dba Icexpress.
Address: 120 Nassau Ave., Inwood,
NY 11096.
Date Revoked: May 1, 2009.
Reason: Failed to maintain valid
bonds.
License Number: 020687NF.
Name: MP Transmec USA LLC dba
TS Lines.
Address: 770 Foster Ave.,
Bensenville, IL 60106.
Date Revoked: May 8, 2009.
Reason: Failed to maintain valid
bonds.
License Number: 001593N.
Name: Robertson Forwarding Co., Inc.
dba RFC Consolidators.
Address: 4469 NW 97th Ave., Miami,
FL 33178.
Date Revoked: May 10, 2009.
Reason: Failed to maintain a valid
bond.
License Number: 013172F.
Name: Yung Hoon Kim dba Conex
International.
Address: 20695 South Western Ave.,
Ste. 136, Torrance, CA 90501.
Date Revoked: May 6, 2009.
Reason: Failed to maintain a valid
bond.
Sandra L. Kusumoto,
Director, Bureau of Certification and
Licensing.
[FR Doc. E9–11757 Filed 5–19–09; 8:45 am]
BILLING CODE 6730–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Nominations to the Advisory
Committee on Blood Safety and
Availability
AGENCY: Department of Health and
Human Services, Office of the Secretary.
ACTION: Notice.
SUMMARY: The Office of Public Health
and Science (OPHS) is seeking
nominations of qualified individuals to
be considered for appointment as
members of the Advisory Committee on
Blood Safety and Availability (ACBSA).
ACBSA is a Federal advisory committee
in the Department of Health and Human
Services. Management support for the
activities of this Committee is the
responsibility of the OPHS.
The qualified individuals will be
nominated to the Secretary of Health
VerDate Nov<24>2008
15:27 May 19, 2009
Jkt 217001
and Human Services for consideration
of appointment as members of the
ACBSA. Members of the Committee,
including the Chair, are appointed by
the Secretary. Members are invited to
serve on the Committee for up to fouryear terms.
DATES: All nominations must be
received no later than 4 p.m. EDT on
June 30, 2009, at the address listed
below.
ADDRESSES: All nominations should be
mailed or delivered to Dr. Jerry
Holmberg, Executive Secretary,
Advisory Committee on Blood Safety
and Availability, Office of Public Health
and Science, Department of Health and
Human Services, 1101 Wootton
Parkway, Suite 250, Rockville, MD
20852. Telephone: (240) 453–8803.
FOR FURTHER INFORMATION CONTACT: Dr.
Jerry Holmberg, Executive Secretary,
Advisory Committee on Blood Safety
and Availability, Office of Public Health
and Science, Department of Health and
Human Services, 1101 Wootton
Parkway, Suite 250, Rockville, MD
20852. Telephone: (240) 453–8803.
A copy of the Committee charter and
roster of the current membership can be
obtained by contacting Dr. Holmberg or
by accessing the ACBSA Web site at
https://www.hhs.gov/bloodsafety. https://
www.hhs.gov/bloodsafety.
SUPPLEMENTARY INFORMATION: The
Advisory Committee on Blood Safety
and Availability advises the Secretary
and the Assistant Secretary for Health.
The Committee provides advice on a
range of policy issues to include: (1)
Definition of public health parameters
around safety and availability of the
blood and blood products, (2) broad
public health, ethical, and legal issues
related to transfusion and
transplantation safety, and (3) the
implications for safety and availability
of various economic factors affecting
product cost and supply.
The ACBSA consists of 20 voting
members. The Committee is composed
of 14 public members, including the
Chair, and six (6) representative
members. The public members are
selected from State and local
organizations, advocacy groups,
provider organizations, academic
researchers, ethicists, private
physicians, scientists, consumer
advocates, legal organizations, and from
among communities of persons who are
frequent recipients of blood or blood
products. There are six (6) individuals
designated to serve as official
representative members of the blood
and blood products industry or
professional organizations. These
representative members shall be from
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
AABB (formerly the American
Association of Blood Banks), Plasma
Protein Therapeutic Association
(PPTA), one of the two major
distributors of blood on a rotating basis,
a trade organization or manufacturer of
blood, plasma, or other tissue test kits
or equipment, and a major hospital
organization that purchases blood and
blood products.
All ACBSA members are authorized
to receive the prescribed per diem
allowance and reimbursement for travel
expenses that are incurred to attend
meetings and conduct Committeerelated business, in accordance with
Standard Government Travel
Regulations. Individuals who are
appointed to serve as public members
are authorized also to receive a stipend
for attending Committee meetings and
to carry out other Committee-related
business. Individuals who are appointed
to serve as representative members for a
particular interest group or industry are
not authorized to receive a stipend for
the performance of these duties.
This announcement is to solicit
nominations of qualified candidates to
fill positions on the ACBSA that are
scheduled to be vacated in the public
member category. The positions are
scheduled to be vacated on March 1,
2010.
Nominations
Persons nominated for appointment
as members of the ACBSA should be
among authorities knowledgeable in
blood banking, transfusion medicine,
plasma therapies, transfusion and
transplantation safety, bioethics, and/or
related disciplines. Nominations should
be typewritten. The following
information should be included in the
package of material submitted for each
individual being nominated for
consideration of appointment: (a) The
name, return address, daytime
telephone number and affiliation(s) of
the individual being nominated, the
basis for the individual’s nomination,
the category for which the individual is
being nominated, and a statement
bearing an original signature of the
nominated individual that, if appointed,
he or she is willing to serve as a member
of the Committee; (b) the name, return
address, and daytime telephone number
at which the nominator may be
contacted. Organizational nominators
must identify a principal contact person
in addition to the contact; and (c) a copy
of a current curriculum vitae or resume
for the nominated individual.
Individuals can nominate themselves
for consideration of appointment to the
Committee. All nominations must
include the required information.
E:\FR\FM\20MYN1.SGM
20MYN1
23721
Federal Register / Vol. 74, No. 96 / Wednesday, May 20, 2009 / Notices
Incomplete nominations will not be
processed for consideration. The letter
from the nominator and certification of
the nominated individual must bear
original signatures; reproduced copies
of these signatures are not acceptable.
The Department of Health and Human
Services is committed to ensuring that
women, minority groups, and physically
challenged individuals are adequately
represented on the Committee.
Nominations of qualified candidates
from these categories are encouraged.
The Department also seeks to have
geographic diversity reflected in the
composition of the Committee.
The Standards of Ethical Conduct for
Employees of the Executive Branch are
applicable to individuals who are
appointed as public members of Federal
advisory committees. Individuals
appointed to serve as public members of
Federal advisory committees are
classified as special Government
employees (SGEs). SGEs are
Government employees for purposes of
the conflict of interest laws. Therefore,
individuals appointed to serve as public
members of the ACBSA are subject to an
ethics review. The ethics review is
conducted to determine if the
individual has any interests and/or
activities in the private sector that may
conflict with performance of their
official duties as a member of the
Committee. Individuals appointed to
serve as public members of the
Committee will be required to disclose
information regarding financial
holdings, consultancies, and research
grants and/or contracts.
Dated: May 14, 2009.
Jerry A. Holmberg,
Executive Secretary, Advisory Committee on
Blood Safety and Availability.
[FR Doc. E9–11675 Filed 5–19–09; 8:45 am]
BILLING CODE 4150–41–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
OMB No.: 0970–0260.
Description: The Office of Head Start
is proposing to renew authority to
collect information regarding the Head
Start transportation requirement
without changes. The transportation
requirement provides the requirement
that each child be seated in a child
restraint system while the vehicle is in
motion, and the requirement that each
bus have at least one bus monitor on
board at all times. Waivers would be
granted when the Head Start or Early
Head Start grantee demonstrates that
compliance with the requirement(s) for
which the waiver is being sought will
result in a significant disruption to the
Head Start program or the Early Head
Start program and that waiving the
requirement(s) is in the best interest of
the children involved.
Respondents: Head Start and Early
Head Start program grants recipients.
Submission for OMB Review;
Comment Request
Title: Extension to HS Transportation
Requirement.
ANNUAL BURDEN ESTIMATES
Instrument
Number of
respondents
Number of
responses per
respondent
Average
burden hours
per response
Total burden
hours
Form .................................................................................................................
275
1
1
275
Estimated Total Annual Burden
Hours: 275.
Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
Administration, Office of Information
Services, 370 L’Enfant Promenade, SW.,
Washington, DC 20447, Attn: ACF
Reports Clearance Officer. All requests
should be identified by the title of the
information collection. E-mail address:
infocollection@acf.hhs.gov.
OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
comments and recommendations for the
proposed information collection should
be sent directly to the following: Office
of Management and Budget, Paperwork
Reduction Project, Fax: 202–395–7245,
Attn: Desk Officer for the
Administration for Children and
Families.
VerDate Nov<24>2008
15:27 May 19, 2009
Jkt 217001
Dated: May 14, 2009.
Janean Chambers,
Reports Clearance Officer.
[FR Doc. E9–11652 Filed 5–19–09; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–N–0546]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Electronic Data
Collection Using MedWatchPlus Portal
and Rational Questionnaire
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
the Paperwork Reduction Act of 1995
(the PRA).
DATES: Fax written comments on the
collection of information by June 19,
2009.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974, or e-mailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–NEW and
title ‘‘Electronic Data Collection Using
MedWatchPlus Portal and Rational
Questionnaire.’’ Also include the FDA
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of Information
Management (HFA–710), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–796–3794.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
E:\FR\FM\20MYN1.SGM
20MYN1
]]>Agencies
[Federal Register Volume 74, Number 96 (Wednesday, May 20, 2009)]
[Notices]
[Pages 23720-23721]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-11675]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Nominations to the Advisory Committee on Blood Safety and
Availability
AGENCY: Department of Health and Human Services, Office of the
Secretary.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Office of Public Health and Science (OPHS) is seeking
nominations of qualified individuals to be considered for appointment
as members of the Advisory Committee on Blood Safety and Availability
(ACBSA). ACBSA is a Federal advisory committee in the Department of
Health and Human Services. Management support for the activities of
this Committee is the responsibility of the OPHS.
The qualified individuals will be nominated to the Secretary of
Health and Human Services for consideration of appointment as members
of the ACBSA. Members of the Committee, including the Chair, are
appointed by the Secretary. Members are invited to serve on the
Committee for up to four-year terms.
DATES: All nominations must be received no later than 4 p.m. EDT on
June 30, 2009, at the address listed below.
ADDRESSES: All nominations should be mailed or delivered to Dr. Jerry
Holmberg, Executive Secretary, Advisory Committee on Blood Safety and
Availability, Office of Public Health and Science, Department of Health
and Human Services, 1101 Wootton Parkway, Suite 250, Rockville, MD
20852. Telephone: (240) 453-8803.
FOR FURTHER INFORMATION CONTACT: Dr. Jerry Holmberg, Executive
Secretary, Advisory Committee on Blood Safety and Availability, Office
of Public Health and Science, Department of Health and Human Services,
1101 Wootton Parkway, Suite 250, Rockville, MD 20852. Telephone: (240)
453-8803.
A copy of the Committee charter and roster of the current
membership can be obtained by contacting Dr. Holmberg or by accessing
the ACBSA Web site at https://www.hhs.gov/bloodsafety. https://www.hhs.gov/bloodsafety.
SUPPLEMENTARY INFORMATION: The Advisory Committee on Blood Safety and
Availability advises the Secretary and the Assistant Secretary for
Health. The Committee provides advice on a range of policy issues to
include: (1) Definition of public health parameters around safety and
availability of the blood and blood products, (2) broad public health,
ethical, and legal issues related to transfusion and transplantation
safety, and (3) the implications for safety and availability of various
economic factors affecting product cost and supply.
The ACBSA consists of 20 voting members. The Committee is composed
of 14 public members, including the Chair, and six (6) representative
members. The public members are selected from State and local
organizations, advocacy groups, provider organizations, academic
researchers, ethicists, private physicians, scientists, consumer
advocates, legal organizations, and from among communities of persons
who are frequent recipients of blood or blood products. There are six
(6) individuals designated to serve as official representative members
of the blood and blood products industry or professional organizations.
These representative members shall be from AABB (formerly the American
Association of Blood Banks), Plasma Protein Therapeutic Association
(PPTA), one of the two major distributors of blood on a rotating basis,
a trade organization or manufacturer of blood, plasma, or other tissue
test kits or equipment, and a major hospital organization that
purchases blood and blood products.
All ACBSA members are authorized to receive the prescribed per diem
allowance and reimbursement for travel expenses that are incurred to
attend meetings and conduct Committee-related business, in accordance
with Standard Government Travel Regulations. Individuals who are
appointed to serve as public members are authorized also to receive a
stipend for attending Committee meetings and to carry out other
Committee-related business. Individuals who are appointed to serve as
representative members for a particular interest group or industry are
not authorized to receive a stipend for the performance of these
duties.
This announcement is to solicit nominations of qualified candidates
to fill positions on the ACBSA that are scheduled to be vacated in the
public member category. The positions are scheduled to be vacated on
March 1, 2010.
Nominations
Persons nominated for appointment as members of the ACBSA should be
among authorities knowledgeable in blood banking, transfusion medicine,
plasma therapies, transfusion and transplantation safety, bioethics,
and/or related disciplines. Nominations should be typewritten. The
following information should be included in the package of material
submitted for each individual being nominated for consideration of
appointment: (a) The name, return address, daytime telephone number and
affiliation(s) of the individual being nominated, the basis for the
individual's nomination, the category for which the individual is being
nominated, and a statement bearing an original signature of the
nominated individual that, if appointed, he or she is willing to serve
as a member of the Committee; (b) the name, return address, and daytime
telephone number at which the nominator may be contacted.
Organizational nominators must identify a principal contact person in
addition to the contact; and (c) a copy of a current curriculum vitae
or resume for the nominated individual.
Individuals can nominate themselves for consideration of
appointment to the Committee. All nominations must include the required
information.
[[Page 23721]]
Incomplete nominations will not be processed for consideration. The
letter from the nominator and certification of the nominated individual
must bear original signatures; reproduced copies of these signatures
are not acceptable.
The Department of Health and Human Services is committed to
ensuring that women, minority groups, and physically challenged
individuals are adequately represented on the Committee. Nominations of
qualified candidates from these categories are encouraged. The
Department also seeks to have geographic diversity reflected in the
composition of the Committee.
The Standards of Ethical Conduct for Employees of the Executive
Branch are applicable to individuals who are appointed as public
members of Federal advisory committees. Individuals appointed to serve
as public members of Federal advisory committees are classified as
special Government employees (SGEs). SGEs are Government employees for
purposes of the conflict of interest laws. Therefore, individuals
appointed to serve as public members of the ACBSA are subject to an
ethics review. The ethics review is conducted to determine if the
individual has any interests and/or activities in the private sector
that may conflict with performance of their official duties as a member
of the Committee. Individuals appointed to serve as public members of
the Committee will be required to disclose information regarding
financial holdings, consultancies, and research grants and/or
contracts.
Dated: May 14, 2009.
Jerry A. Holmberg,
Executive Secretary, Advisory Committee on Blood Safety and
Availability.
[FR Doc. E9-11675 Filed 5-19-09; 8:45 am]
BILLING CODE 4150-41-P
